Programmed cell death-1 ligand-1(PD-L1)overexpression in cancer cells accelerates tumor progression.PD-L1 possesses two main pro-oncogenic functions.First,PD-L1 is a strong immunosuppressive molecule that inactivates ...Programmed cell death-1 ligand-1(PD-L1)overexpression in cancer cells accelerates tumor progression.PD-L1 possesses two main pro-oncogenic functions.First,PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1.Second,PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival,regulate stress responses and confer resistance toward pro-apoptotic stimuli,such as interferons.Here,we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1,describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.展开更多
基金the following funding:FIS project(FIS.PI17/02119)from the Institute of Health Carlos Ⅲ in Spain,the AECC project(PROYE16001ESCO)the Crowdfunding Project“Precipita”,Spanish Foundation for Science and Tecnology(FECYT).
文摘Programmed cell death-1 ligand-1(PD-L1)overexpression in cancer cells accelerates tumor progression.PD-L1 possesses two main pro-oncogenic functions.First,PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1.Second,PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival,regulate stress responses and confer resistance toward pro-apoptotic stimuli,such as interferons.Here,we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1,describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.
